A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)

Inclusion Criteria:

- Histologically or cytologically documented NSCLC; Patients must be M0. Patients with
T1-T2 with N2 or T3N1-2 are eligible, if inoperable. Patients with T4 with any N or
any T with N2 or N3 disease are eligible if unresectable.

- Patients with tumors adjacent to a vertebral body are eligible as long as all gross
disease can be encompassed in the radiation boost field. The boost volume must be
limited to < 50% of the ipsilateral lung volume.

- Patients with Zubrod performance status 0-1

- Adequate hematologic function

- FEV1 with ≥ 1200 cc or ≥ 50% predicted

Exclusion Criteria:

- Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for
any reason and/or surgical resection of present cancer

- Exudative, bloody, or cytologically malignant effusions

- Prior therapy with any molecular targeted drugs (for lung cancer)

- Active pulmonary infection not responsive to conventional antibiotics

- Clinically significant cardiovascular event (e.g. myocardial infarction, superior
vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart
disease >2 (see Appendix B) within 3 months before entry; or presence of cardiac
disease that, in the opinion of the Investigator, increases the risk of ventricular
arrhythmia.

- Patients with > grade 1 neuropathy